Company intelligence / Profile preview

Theoria Science

Tokyo, Japan

Ownership: Private
Development stage: Other

Overview

Theoria Science is developing an exosome assay called ExoScreen based on Perkin Elmer's AlphaLISA assay, with applications in colorectal cancer diagnosis. The company has also filed patents relating to drug delivery systems for passing through the blood-brain barrier and diagnosis, prevention, and treatment of brain metastases.

Therapeutic areas: Oncology
Modalities: Exosome-based therapy
Industry: Biotech

Beyond the preview

Go deeper on Theoria Science.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theoria Science.

Explore the full profile